

Opinion Article

Effect of chronic administration of *Boerhaavia diffusa* Linn. leaf extract on experimental diabetes in rats

Rao K. Nalamolu¹, Krishna M. Boini^{2,3}, Srinivas Nammi^{2,3Φ}

¹Pharmacology Division, GITAM Dental College, Visakhapatnam, Andhra Pradesh, India

²Pharmacology Division, Andhra University, Department of Pharmaceutical Sciences, Visakhapatnam, Andhra Pradesh, India

³Department of Physiology, University of Tübingen, D 72076 Tübingen, Germany

Abstract

Purpose: The root and aerial parts of *Boerhaavia diffusa* Linn. (Nyctaginaceae) were used in Ayurveda for the treatment of diabetes. The present study is aimed at evaluating the antidiabetic activity of chloroform extract of *Boerhaavia diffusa* leaves on chronic administration in streptozotocin-induced non-insulin-dependent diabetes mellitus (NIDDM) model diabetic rats.

Methods: The blood glucose lowering activity of the leaf extract was studied in streptozotocin-induced (65 mg/kg, i.v.) NIDDM model diabetic rats after oral administration of the extract at daily doses of 50, 100 and 200 mg/kg body weight for four weeks and compared with glibenclamide. Blood samples were collected from the tail vein before and also at weekly intervals for four weeks from the first dose of drug administration and blood glucose was analyzed by glucose-oxidase method using a visible spectrophotometer.

Results: The leaf extract of *B. diffusa* produced dose-dependent reduction in blood glucose in streptozotocin-induced NIDDM rats comparable to that of glibenclamide. The results indicate that the reduction in blood glucose produced by the extract is probably through rejuvenation of pancreatic β -cells or through extrapancreatic action.

Conclusion: The chloroform extract of *Boerhaavia diffusa* has significant antidiabetic activity and this supports the traditional usage of the plant by Ayurvedic physicians for the control of diabetes.

Key words: Blood glucose, *Boerhaavia diffusa*, Diabetes mellitus Streptozotocin, Rats

Φ To whom correspondence should be addressed: E-mail: nammi@rediffmail.com or krishnamurthyboini@yahoo.com

Introduction

Diabetes mellitus, an endocrine disorder, is characterized by hyperglycemia and affects a large number of people worldwide. By the year 2010, the total number of people worldwide with diabetes is projected to reach 239 millions¹. In modern medicine, no satisfactory effective therapy is still available to cure diabetes mellitus². Currently available therapeutic options such as dietary modification, oral hypoglycemics and insulin have limitations of their own in treating non-insulin dependent diabetes mellitus (NIDDM)³⁻⁴. Therefore, the search for more effective and safer hypoglycemic agents has continued to be an area of active research. The World Health Organization has recommended the evaluation of the effectiveness of medicinal plants in condition where the conventional allopathic treatment of diabetes is not adequate⁵⁻⁶.

In the indigenous Indian system of medicine (Ayurveda), many herbal medicines have been recommended for the treatment of diabetes or 'madhumeha' and some of them have been experimentally evaluated. *Boerhaavia diffusa* Linn. (Nyctaginaceae) is a small perennial creeping herb, commonly known as "Red hogweed" and distributed widely all over in India, and in many other countries. The root and the whole plant are used as an Ayurvedic medicine in India and Unani medicine in Arab countries for the treatment of diabetes, stress, dyspepsia, abdominal pain, inflammation, jaundice, enlargement of spleen, congestive heart failure and bacterial infections⁷⁻¹¹. The plant is known to possess anti-inflammatory¹²⁻¹³, anticonvulsant¹⁴, antifibrinolytic¹⁵, diuretic¹⁶, hepatoprotective¹⁷⁻²⁰ and immunomodulatory²¹⁻²² activities. It has also been reported to be useful in the treatment of elephantiasis, night blindness, corneal ulcers and nephritic syndrome²³⁻²⁶.

Recently, the aqueous leaf extract of the plant has been studied for its antidiabetic

effect in alloxan-induced diabetic rats²⁷⁻²⁸. The present investigation is aimed at evaluating the antidiabetic activity of the chloroform extract of the plant leaves on chronic treatment of streptozotocin-induced NIDDM model diabetic rats.

Experimental

Chemicals

Glibenclamide was a generous gift sample from Hoechst Pharmaceuticals, Mumbai, India. Glucose assay kit was obtained from the Diagnostic Division of Dr. Reddy's Laboratories, Hyderabad, while streptozotocin was purchased from Sigma-Aldrich, St. Louis, USA.

Plant Material and Extraction

Fresh leaves of *B. diffusa* were purchased from local traders in Visakhapatnam, India and shade dried for about two weeks. The leaves were botanically authenticated and a voucher specimen has been preserved for future reference. The dry leaf powder (3 kg) was extracted with chloroform in Soxhlet apparatus for 24 hr and the extract was evaporated to dryness under vacuum in a vacuum desiccator (268 g).

Animals

Adult male Sprague-Dawley rats (National Institute of Nutrition, Hyderabad) weighing 250-300 g were used in the study. They were divided into 6 groups of six each and were provided with standard pellet diet (Ratan Brothers, Hyderabad) and water *ad libitum*. All rats were acclimatized to the laboratory conditions for at least 10 days prior to the experiment and were maintained in a well-ventilated animal house with 12-hr light and dark cycle. As appropriate, the animals were fed with the standard pellet diet throughout the experiment, except for 12 hr prior to blood collection when only water was given.

The experimental protocol was been approved by the Institutional Animal Ethics Committee and by the animal regulatory body of the India government (Regd. No. 516/01/A/CPCSEA).

The rats assigned to groups I to V were rendered diabetic by injecting streptozotocin (65 mg/kg, i.v.; dissolved in 0.1 M citrate buffer; pH 4.5) after a baseline blood glucose estimation was done. After 2 to 3 days, the condition of diabetes was assessed by periodic examination of blood glucose using glucose-assay sticks. Only animals with stable blood glucose above 300 mg/dl were selected for the study.

B. diffusa extract, in the form of a suspension in 0.1% sodium CMC at daily doses of 50, 100 and 200 mg/kg body weight, were administered orally to the rats in groups I, II & III, respectively for 4 weeks. Rats in group IV received a similar treatment with glibenclamide (25 µg/kg) daily for 4 weeks while the rats in groups V and VI received 3 ml of 0.1% sodium carboxymethylcellulose and were used as diabetic and normal controls, respectively.

Collection of Blood and Analytical Procedure

Blood samples were collected before and also at weekly intervals for 4 weeks from the from the tail vein of the rats from the first

dose of drug administration. Glucose-Oxidase assay method²⁹⁻³⁰ was used to determine the blood glucose.

Data and Statistical Analysis

Data are expressed as means ± standard error of means of at least triplicate determinations. Statistical analysis was carried out using one-way analysis of variance (ANOVA) and Dunnett's *t*-test. At 95% confidence interval *p* values less than 0.05 were considered to be significant.

Results and Discussion

The present study was conducted to study the antidiabetic activity of *B. diffusa* in rats to provide scientific evidence for its traditional usage in the control of diabetes. From the results obtained, it is obvious that chronic administration of *B. diffusa* extract to streptozotocin-induced NIDDM rats produced blood glucose reduction in a dose-dependent manner. To determine whether there was a statistically significant difference in hypoglycemia achieved by the three doses (50, 100 and 200 mg/kg, p.o.) chronically administered, the data were compared by using one-way analysis of variance and the individual groups were compared with control group using Dunnett's *t*-test. The extract of *B. diffusa* produced a significant reduction in blood glucose after 1

Table 1: Percentage blood glucose reduction produced by *B. diffusa* after chronic oral administration in streptozotocin-induced NIDDM model rats

Rats	Percent Blood Glucose Reduction (n=6)			
	Week 1	Week 2	Week 3	Week 4
Normal Control	-9.65 ± 1.20	4.05 ± 0.84	7.58 ± 2.59	-4.36 ± 1.64
Diabetic Control	-10.35 ± 9.81	-15.31 ± 16.58	-18.93 ± 10.02	-20.33 ± 19.35
Treated with 50 mg/kg of extract	4.34 ± 2.43	9.56 ± 4.66	13.82 ± 8.57*	16.30 ± 4.56
Treated with 100 mg/kg of extract	10.32 ± 8.08*	18.60 ± 9.89*	24.51 ± 8.24***	29.98 ± 6.94*
Treated with 200 mg/kg of extract	25.37 ± 10.50*	28.32 ± 8.68**	33.04 ± 7.13***	38.63 ± 9.46**
Treated with 25 µg/kg glibenclamide	66.20 ± 9.58***	60.60 ± 7.93***	65.74 ± 8.22***	59.01 ± 9.89***

Values are means ± S.E.M; n = number of animals; **p*<0.05; ***p*<0.01; ****p*<0.001.

week of treatment and increased furthermore at the end of 4th week by 30% ($p < 0.01$) and 38.6% ($p < 0.001$) at doses of 100 and 200 mg/kg body weight, respectively although the lowest dose (50 mg/kg) tested could produced significant change only after 3 weeks of treatment (Table 1). Glibenclamide (25 μ g/kg, administered orally, p.o.) produced a significant reduction ($p < 0.01$) compared to diabetic control at the end of 1st week (66.2%). The results obtained in this study are in good agreement with those observed by previous investigators in alloxan-induced diabetic rats²⁷⁻²⁸.

Streptozotocin, a betacytotoxin induces a "chemical diabetes" in a wide variety of animal species through a massive destruction of β -cells of the islets of Langerhans and resulting in reduced synthesis and release of insulin³². It is well established that sulphonylureas produce hypoglycemia by increasing the secretion of insulin from pancreas and by increasing the glycogen deposition in the liver^{33,34}. These compounds are active in mild streptozotocin-induced diabetes whereas they are inactive in intense streptozotocin diabetes (nearly all β -cells have been destroyed). Since our results showed that glibenclamide reduced blood glucose levels in hyperglycemic animals, the state of diabetes is not severe^{35,36}. Streptozotocin-treated animals receiving the leaf extract of *B. diffusa* showed rapid normalization of blood glucose levels in comparison to control and this could be due to the possibility that some β -cells were still active and were acted upon by *B. diffusa* to exert their insulin releasing effect. This suggests that the mode of action of the active ingredients of *B. diffusa* is probably mediated by an enhanced secretion of insulin, like sulphonylureas. Earlier investigations²⁷⁻²⁸ also revealed an insulin releasing mechanism by the aqueous leaf extract of *B. diffusa* and lend support for the results observed in this study. However, the possibility of enhanced tissue glucose utilization by *B. diffusa* cannot be ruled out.

Further work on fractionation, purification, identification of active principle(s) and detailed mechanistic evaluation on the leaves of *B. diffusa* is yet to be carried out.

References

1. American Diabetes Association. Clinical practice recommendations. *Diabetes Care* 1997; 20: S1-S70.
2. Sumana G, Suryawashi SA. Effect of *Vinca rosea* extracts in treatments of alloxan diabetes in male albino rats. *Ind J Expt Biol* 2001; 39: 748 – 758.
3. Berger S. Incidence of severe side effects during therapy with sulphonylurea and biguanides. *Hormone Metab Res* 1985; 17: 111–115.
4. Hupponen R. Adverse cardiovascular effects of sulphonylurea drugs: Clinical significance. *Med Toxicol* 1978; 2: 190–209.
5. WHO Expert committee on diabetes mellitus. Second report. Technical report series World Health Organization, Geneva, 1980, 646.
6. Upathaya V, Pandey K. Ayurvedic approach to diabetes mellitus and its management by indigenous resources. In: Bajaj JS (ed.), *Diabetes mellitus in developing countries*, New Delhi, Interprint, 1984, 375-377.
7. Nadkarni, KM. *Boerhaavia diffusa*. Indian Materia Medica, ed 3, Mumbai, Popular Book Depot, 1954, 202-207.
8. Kirtikar KR, Basu, BD. *Boerhaavia diffusa*. Indian Medicinal Plants, ed 2, Allahabad, Lalit Mohan Basu Publications, 1933, 1052-1054.
9. Chopra RW, Chopra IC, Handa KL, Kapur LD. Medicinal plants in diabetes. In: P.Gupta (ed), *Indigenous Drugs of India*, ed 2, Calcutta, India, Dhar and Sons Ltd, 1958, 314-316.
10. Chopra RN, Nayar SL, Chopra IC. Glossary of Indian Medicinal Plants. New Delhi, National Institutes of Science Communication, 1996.
11. Aslam M. Asian medicine and its practise in Britain. In: Evans, WC (ed.). *Pharmacognosy*, London, UK, Saunders Company Ltd, 1996, 499-500.
12. Bhalla TN, Gupta MB, Bhargava KP. Anti-inflammatory activity of *Boerhaavia diffusa*. *J Res Ind Med* 1971; 6: 11-15.
13. Hiruma-Lima CA., Gracioso JS, Bighetti EJ, Germansen RL, Souja BAR. The juice of fresh leaves of *Boerhaavia diffusa* L.(Nyctaginaceae) markedly reduces pain in mice. *J Ethnopharmacol* 2000; 71: 267-274.
14. Mudgal V. Studies on medicinal properties of *Convolvulus pluricaulis* and *Boerhaavia diffusa*. *Planta Med* 1975; 28: 62-68.

15. Jain GK, Khanna NM. Punarnavoside: a new antifibrotic agent from *Boerhaavia diffusa* L. *Ind J Chem* 1989; 28: 163-166.
16. Singh RP, Shokala KP, Pandey BL, Singh, RG, Usha, Singh R. Recent approach in clinical and experimental evaluation of diuretic action of Punarnava (*Boerhaavia diffusa*) with special effect to nephrotic syndrome. *J Ind Med Res* 1992; 11: 29-36.
17. Chakraborty KK, Handa SS. Antihepatotoxic investigations of *Boerhaavia diffusa* L. *Ind Drugs* 1989; 27: 161-166.
18. Chandan BK, Sharma AK, Anand KK. *Boerhaavia diffusa*: a study of its hepatoprotective activity. *J Ethnopharmacol* 1991; 31: 299-307.
19. Rajukumari G, Sarla A, Agarwal SS. Hepatoprotective activity of *Boerhaavia diffusa* Linn. against country made liquor induced hepatotoxicity in albino rats fed on controlled calorie diet. *Ind J Pharmacol* 1991; 23: 264-267.
20. Rawat AKS, Mehrotra S, Tripathi SC, Shome U. Hepatoprotective activity of *Boerhaavia diffusa* L. roots – a popular Indian ethnomedicine. *J Ethnopharmacol* 1997; 56: 61-66.
21. Mehrotra S, Mishra KP, Maurya R, Srimal RC, Singh VK. Immunomodulation by ethanolic extract of *Boerhaavia diffusa* roots. *Int Immunopharmacol* 2002; 2: 987-996.
22. Mehrotra S, Singh VK, Agarwal SS, Maurya R, Srimal, R.C. Antilymphoproliferative activity of ethanolic extract of *Boerhaavia diffusa* roots. *Exptl Mol Pathol* 2002; 72: 236-242.
23. Mishra J, Singh R. The effect of indigenous drug *Boerhaavia diffusa* on kidney regeneration. *Ind J Pharmacol* 1980; 12: 59-64.
24. Singh RH, Udupa KN. Studies on the Indian indigenous drug Punarnava (*Boerhaavia diffusa* L.) Part I, Identification and pharmacological studies. *J Res Ind Med* 1972; 7: 1-12.
25. Singh RH, Udupa KN. Studies on the Indian indigenous drug Punarnava (*Boerhaavia diffusa* L.) Part III. Experimental and pharmacological studies. *J Res Ind Med* 1972; 7: 17-27.
26. Singh RH, Udupa KN. Studies on the Indian indigenous drug Punarnava (*Boerhaavia diffusa* L.) Part IV. Preliminary controlled clinical trial in nephrotic syndrome. *J Res Ind Med* 1972; 7: 28-33.
27. Chude MA, Orisakwe OJ, Afonne OJ, Gamaniel KS, Vongtau OH, Obi E. Hypoglycemic effect of the aqueous extract of *Boerhaavia diffusa* leaves. *Ind J Pharmacol* 2001, 33: 215–216.
28. Pari L, Satheesh MA. Antidiabetic activity of *Boerhaavia diffusa* L.: Effect on hepatic key enzymes in experimental diabetes. *J Ethnopharmacol* 2004; 91: 109-113.
29. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. *J Clin Pathol* 1969; 22: 485-520.
30. Glynn JP, Kendal SE. In: Varley H, Gowenlock AH, Bell M (eds.), *Practical Clinical Biochemistry* 5th edition, CBS Publishers, New Delhi, Vol I: 1991 389-391.
31. Baily CJ, Flatt, PR. Antidiabetic drugs, new developments. *Ind Biotechnol* 1986; 6:139 – 142.
32. Rerup CC. Drugs producing diabetes through damage of insulin secreting cells. *Pharmacol Rev* 1970; 22: 485 – 520.
33. Grodsky GM, Epstein GH, Fanska R, Karam, JH. Pancreatic action of sulphonylureas. *Fed Proc* 1971; 36: 2719 – 2728.
34. Yallow RS, Black H, Villazan M, Berson SA. Comparison of plasma insulin levels following administration of tolbutamide and glucose. *Diabetes* 1960; 9: 356 – 362.
35. Krall LP, Chabot VA. Oral hypoglycemic agent update. *Med Clin North Am* 1978; 62: 681-694.
36. Grunberger G, Ryan J, Gorden P. Sulfonylureas do not affect insulin binding or glycemic control in insulin-dependent diabetics. *Diabetes* 1982; 31: 890-896.;43(9):624-7.